A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO ...

Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at ...

Eli Lilly’s weekly insulin injection efsitora alfa secured two late-stage victories on Thursday in a potential blow to rival ...

BioMarin executives sought to calm an anxious investor base Wednesday with a public address and pledge to achieve a nearly 50 ...

Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive ...

The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial ...

The intellectual property landscape for newer gene-editing technologies, like that for CRISPR-Cas9, remains unclear and hard ...

The investigational injection fosgonimeton appeared to have better efficacy in patients with more severe disease, according ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported ...